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Background & Aims: To investigate whether mitogen- carcinogenesis. Alternatively, spontaneous mutations at
activated protein kinase (MAPK) cascades might play a the cellular level could enable individual cells to prolifer-
role in the progression of colon cancer, c-Jun N-terminal ate rapidly, leading to clonal expansion and an overall
kinase (JNK) and extracellular signal regulating kinase increase in intestinal proliferation. Unlike the later events
(ERK) activity during colonic tumorigenesis were exam- in carcinogenesis in which specific mutations have been
ined. Methods: The 1,2-dimethylhydrazine (DMH)-in- described, the molecular events that characterize intesti-
duced colon carcinoma model was used to study the nal hyperproliferation have not yet been identified.
activation of these kinases during intestinal carcino-
Changes in proliferation can occur as a consequencegenesis. Male Sprague–Dawley rats were injected with
of the activation of signal transduction pathways by mi-DMH for 24 weeks. Normal-appearing intestinal mu-
togenic stimuli. Signal cascades that activate memberscosa from control and treated animals and DMH-in-
of the mitogen-activated protein kinase (MAPK) familyduced intestinal tumors were assayed for JNK and ERK
of proteins result in diverse cellular responses, includingactivity using solid phase in vitro kinase assays. Tu-
mors were typed for mutations in the K-ras gene. Re- proliferation, differentiation, and neoplastic transforma-
sults: There was little or no difference in JNK and ERK tion. These changes are mediated by the activation of
activity in hyperproliferative mucosa from DMH-treated transcription factors, including the activating protein
animals compared with normal mucosa from control (AP)-1 transcription factor, which leads to changes in
animals. However, in 16 colonic neoplasms, an average gene expression. AP-1 is implicated in both proliferation
of 23-fold and 29-fold increases in JNK and ERK activi- and tumorigenesis.8–10
ties were observed, respectively, over control levels. Extracellular signals, such as cytokines or growth fac-
In addition, activating protein-1 binding was strongly
tors, stimulate signal cascades by binding to their specific
induced in the colonic tumors. Activation did not corre-
receptors.11 This leads to activation of intermediate sig-late with the presence of mutations in K-ras. Conclu-
naling molecules, such as the small guanosine triphos-sions: Both the JNK and ERK MAPKs are highly acti-
phate binding protein Ras, which transduce signals byvated during late progression of colorectal carcinoma.
activating a cascade of other serine/threonine kinases.This change is dependent on the tumorigenic state
Activation of these upstream S/T kinases leads to activa-rather than changes in proliferation.
tion of dual-specificity kinases, such as MEK and SEK
( JNKK), which then phosphorylate extracellular signal
C regulating kinase (ERK) and c-Jun N-terminal kinaseolonic carcinogenesis is a multistep process involv-ing the accumulation of genetic mutations, includ-
( JNK), respectively. Activated ERK and JNK translo-
ing both the activation of oncogenes and the loss of tumor
cate to the nucleus, where they directly activate transcrip-
suppressor genes.1 Specific genetic alterations have been
tion factors, including AP-1.11 In addition to ras signal-
observed through the progression from a normal colonic
ing pathways leading to activation of AP-1 through JNK
epithelium to a hyperproliferative epithelium, adenoma,
and ERK proteins, the JNK pathway can also be stimu-
carcinoma, and invasive carcinoma. Patients with adeno- lated by a ras-independent mechanism.12
mas or carcinomas have a hyperproliferative epithelium
compared with that of control subjects, even at sites Abbreviations used in this paper: AP, activating protein; DMH, 1,2-
dimethylhydrazine; ERK, extracellular signal regulating kinase; JNK,distant from the adenoma or tumor.2–7 A field effect has
c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase;been hypothesized, whereas global increases in intestinal
SDS, sodium dodecyl sulfate.
proliferation at the cellular level increase the likelihood q 1997 by the American Gastroenterological Association
0016-5085/97/$3.00of new mutations, the accumulation of which leads to
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refeeding. Control animals were fed ad libitum and killed atThe 1,2-dimethylhydrazine (DMH)-induced colon
the 18-hour time point. Sample tissue from the jejunum, ce-carcinoma model provides a reproducible system to study
cum, and transverse colon was immediately flash frozen incolonic carcinogenesis in vivo in rodents. Long-term
liquid nitrogen or fixed in 10% buffered formalin.treatment with DMH induces necrosis of colonic crypt
cells, resulting in a compensatory proliferative response Whole Cell Extracts
that leads to hyperplasia, dysplasia, and eventually tu-
Intestinal mucosa was separated from the underlyingmorigenesis.13 Clinical signs in treated animals mimic
muscularis mucosa by scraping a glass slide along the bowel
those seen in human disease, including diarrhea, bloody
wall. The dissection technique was confirmed by light micros-
stools, and weight loss.14–16 Similar to human colorectal copy. Mucosal cells were lysed in Dignam C buffer (420 mmol/
cancers, about 40%–60% of intestinal tumors found in L NaCl, 1.5 mmol/L MgCl2 , 20 mmol/L HEPES [pH 7.0],
DMH-treated animals have a mutated K-ras gene.17,18 0.2 mmol/L EDTA, 25% glycerol, and 0.5 mmol/L dithiothre-
Despite recent investigations into the role of K-ras muta- itol)21 with protease and phosphatase inhibitors (0.5 mmol/L
tions in colorectal carcinoma, the physiological meaning Pefabloc [Boehringer Mannheim Corp., Indianapolis, IN], 0.1
mmol/L 4-nitrophenyl phosphate, 0.04 mmol/L b-glycero-of these changes remains poorly understood. Although
phosphate, 0.05 mmol/L Na3VO4, 40 mg/mL bestatin, 2 mg/it seems that mutation of K-ras can mediate the morpho-
mL aprotinin, 0.54 mg/mL leupeptin, and 0.7 mg/mL pepstatinlogical changes and altered growth properties of trans-
A) using disposable homogenizers kept between 0–47C at allformed cells,19 it does not seem to be required for the
times. Tumors were lysed directly by homogenation in Dig-tumorigenicity of these cells20 or for tumorigenesis in
nam C buffer (plus inhibitors) after mincing with a razor blade.vivo.
Protein concentration was determined using the Bio-Rad Pro-
In this study, the DMH-induced colon carcinoma
tein Assay (Bio-Rad Laboratories, Hercules, CA).
model was used to investigate the activation of ERK and
JNK MAPKs in vivo at the normal, hyperproliferative, Ornithine Decarboxylase Activity Assay
adenoma, and carcinoma stages of tumorigenesis. In addi- Ornithine decarboxylase activity was measured in the
tion, we used a fasting/refeeding model as an independent jejunum and transverse colon tissue samples of rats in the
method for examining ERK and JNK kinases in hyper- fasting and refeeding experiment by a modification of the stan-
proliferative intestinal mucosa in vivo. This report dem- dard method.22 Reactions containing 12 mmol/L dithiothrei-
onstrates strong activation of AP-1 and its regulating tol, 1.72 mmol/L DL-ornithine, and 0.5 mCi of DL-[14C]-
ornithine were incubated for 1 hour at 377C, and the CO2kinases in the later stages of colonic carcinogenesis. Fur-
released trapped on filter paper was soaked in 200 mL benzetho-thermore, we show that this change does not occur during
nium hydroxide. Reactions were stopped by the addition ofhyperproliferation, but only in adenomas and carcinomas.
30% trichloroacetic acid and subsequently counted in a scintil-
lation counter. A difluoromethylornithine-corrected blank wasMaterials and Methods
used for all calculations. The protein concentration of the ho-Carcinogen Treatment
mogenates was determined by the Lowry method.23 The orni-
Male Sprague–Dawley rats initially weighing Ç240 thine decarboxylase activity was calculated by subtracting the
g (Harlan, Indianapolis, IN) were injected subcutaneously with quantity of CO2 released by nonspecific decarboxylation and
either 25 mg/kg body wt of DMH (Sigma Chemical Co., expressed as picomoles CO2 released per milligrams of protein
St. Louis, MO) in 1 mmol/L ethylenediaminetetraacetic acid per hour.
(EDTA) buffer, pH 6.5, or buffer alone at weekly intervals for
Mobility Shift Assay24 weeks. Body weight, general health, and the appearance of
any signs of disease (bloody stools or diarrhea) were monitored AP-1 DNA binding activity was determined using a
throughout the course of treatment. The animals were killed radiolabeled double-stranded consensus AP-1 site (5* TAA-
25 weeks after the onset of treatment, and normal-appearing AGCATGAGTCAGGACACCTC 3*) from the human colla-
tissue from the jejunum, cecum, and transverse colon was re- genase gene as a probe in a reaction with 5 mg of protein, as
moved, as well as any tumors. Tissue was immediately flash described previously.24 Supershift reactions included 1 mL of
frozen in liquid nitrogen or fixed in 10% buffered formalin. anti–c-Jun, anti–c-Fos, or anti-JunB antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA). The use of whole cell extracts
Fasting/Refeeding Treatment rather than nuclear extracts in the electrophoretic mobility
shift assay experiment was necessitated by the tissue beingMale Sprague–Dawley rats weighing Ç220 g were
either fasted for 48 hours or fed a pelleted diet (Purina Rat flash frozen. However, both c-Fos and c-Jun have been pre-
viously shown to be localized in the nucleus,25 and the use ofChow; Ralston-Purina Co., St. Louis, MO) ad libitum with
water available in all cages. Fasted animals were either not whole cell extracts to measure DNA binding activity has been
well documented.26,27refed (0 hour) or refed and killed at 1, 4, or 18 hours after
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turer’s instructions. Between 30 and 50 subclones from eachKinase Assays
tumor were then screened for K-ras mutations by oligonucleo-
JNK activity was assessed in intestinal mucosa samples
tide hybridization, performed as described previously.18
using an in vitro kinase assay as described previously.28 Briefly,
recombinant guanosine triphosphate-c-Jun protein was used Statistical Analysis
as a substrate in a reaction containing 25 mg of whole cell
For the DMH model, proliferation in controls wasextracts (prepared from jejunum, transverse colon, or tumor
compared with that of treated animals using Wilcoxon’s ranktissue) and [g-32P]adenosine triphosphate (ATP). ERK activity
sum test.31 The same test was used to compare levels foundwas assessed similarly by an in vitro immune complex kinase
in controls to average tumor levels in treated animals. Theassay.29 Immunoprecipitation was performed on whole cell
Wilcoxon’s rank sum test is a nonparametric test that uses theextracts using an anti-ERK-2 antibody (Santa Cruz, C-14;
ranks rather than the actual measures to test for a differencecross-reactive with ERK-1) and protein A–Sepharose beads.
between two groups. No assumptions about the underlyingImmunoprecipitates were then incubated in a kinase reaction
distribution of the data are necessary. For comparisons of tumorincluding recombinant guanosine triphosphate-Elk protein
to nontumorous tissue from the same animal, average prolifera-(containing the C-terminal portion of c-Elk) as a substrate and
tion was calculated when there was more than one tumor,[g-32P]ATP.
and pairwise differences between tumor levels and levels in
nontumorous tissues were obtained. The Wilcoxon’s signedWestern Blot Analysis
rank test31 was used to test the hypothesis that the median
Western blot analysis was used to measure JNK-1 and difference between tumor levels and nontumorous tissue (for
ERK protein levels. Proteins from whole cell extracts were first the group of treated animals) was equal to zero.
fractionated by 12.5% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) and then transferred to polyvi- Results
nylidene difluoride membranes (Immobilon-P; Millipore
DMH Induction of Hyperproliferation andCorp., Bedford, MA). After blocking for nonspecific binding,
Tumors in Rat Intestinesthe membranes were probed with either anti–JNK-1 (Phar-
mingen, San Diego, CA; 1:250), anti–ERK-2 (Santa Cruz, C- Twelve male Sprague–Dawley rats were injected
14; 1:400), or anti–active-ERK (Promega Corp., Madison, subcutaneously with 25 mg/kg body wt of DMH at
WI; 1:2000) antibodies followed by appropriate horseradish weekly intervals for 24 weeks. Six control animals were
peroxidase–conjugated secondary antibodies (1:1000). Addi- injected only with buffer and monitored similarly.
tional blots contained JNK-1 protein immunoprecipitated Twenty-five weeks after the onset of treatment, the ani-
from whole cell extracts before electrophoresis. An enhanced
mals were killed and the small and large intestine excisedchemiluminescence system was used for detection of the pro-
by incisions in the duodenum and rectum. A total of 20teins (Amersham International plc, Buckinghamshire, En-
tumors were found in 11 of the 12 treated animalsgland). Before immunoblotting, ponceau S staining was used
(91.7%), with 4 animals having 1 tumor (25%), 5 ani-to demonstrate equal protein loading.
mals having 2 tumors (41.7%), and 2 animals having 3
tumors (16.7%). Histological examination confirmedGenotyping for K-ras Mutations
that most samples appearing abnormal on gross examina-DNA was extracted from paraffin-embedded samples
tion were adenomas or carcinomas (Table 1). These variedas described.30 A 116–base pair DNA fragment including
in regard to their histological stage, size, and location.codons 12 and 13 of the K-ras gene was amplified using the
To determine the proliferative status of the normal-polymerase chain reaction and oligonucleotides from exon 1
appearing intestinal mucosa from the treated and controlas primers (5* CCTGCTGAAAATGACTGAGTA 3* and 3*
CCTACTTATACTAGGATGCT 5*). Five microliters of crude animals, whole crypt mitotic counts were done. Significant
DNA extract was amplified in a 50-mL reaction containing increases in the number of dividing cells were found in
0.15 mmol of each primer and 0.625 U of Taq polymerase both the jejunum and transverse colon of DMH-treated
using an automated DNA thermal cycler (Perkin-Elmer Cetus, animals compared with controls (Figure 1; P Å 0.0011).
Norwalk, CT) for 40 cycles of denaturation (907C, 20 seconds)
and annealing (507C, 20 seconds). Extension occurred during AP-1 Binding Is Induced in Neoplasia
the increase in temperature between the annealing and dena-
One of the downstream targets of MAPK signalturation steps. Control reactions containing all reagents except
pathways is the AP-1 transcription factor, consisting ofDNA were performed to confirm the absence of contamination.
Jun-Jun family homodimers or Jun-Fos family heterodim-Amplified DNA products were analyzed by gel electrophoresis
ers. Because AP-1 is thought to play a role in proliferationon 5% polyacrylamide gels. Polymerase chain reaction prod-
and tumorigenesis, we investigated AP-1 activation byucts were subcloned into the pCR vector using the TA cloning
kit (Invitrogen Corp., San Diego, CA) following the manufac- assaying AP-1 binding activity. Using the DNA mobility
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Table 1. Analysis of Intestinal Tumors in DMH-Treated Rats
Tumor Histology Location Size (cm) K-ras
T0 Infiltratin carcinoma Jejunum 1.50 13D
T1 Invasive epithelial tumor Jejunum 1.00 13A
T2 Epithelial atypia, invasive carcinoma, irregular glands Transverse colon 0.20 WT
T3 Epithelial atypia, ulcerated carcinoma Jejunum 0.30 12D
T4 Epithelial atypia, intramucosal carcinoma Transverse colon 0.30 12D
T5a Normal epithelium Transverse colon 0.50 ND
T6 Minimal invasive epithelial carcinoma Jejunum 0.70 WT
T7 Adenomatous polyp with multiple lumina Transverse colon 0.40 12D
T8a Normal epithelium Transverse colon 0.40 WT
T9 Invasive epithelial carcinoma Jejunum 0.50 12D
T10 Epithelial atypia, invasive carcinoma Transverse colon 0.40 WT
T11 Epithelial atypia, invasive carcinoma Transverse colon 0.40 WT
T12 Epithelial atypia, glandular epithelial invasive carcinoma Duodenum 0.20 12D
T13 Villous adenoma, carcinoma Duodenum 0.50 WT
T14 Frankly invasive intramucosal carcinoma Transverse colon 0.70 12D
T15 Invasive epithelial carcinoma Duodenum 0.40 WT
T16 Intramucosal carcinoma Transverse colon 1.00 12D
T17a Normal epithelium, lymphoid nodules Jejunum 0.50 WT
T18 Adenomatous polyp Transverse colon 0.30 WT
T19 Adenomatous polyp Jejunum 0.20 12D
ND, not done; WT, wild type (12G, 13G).
aSample that was omitted from the tumor group based on histological characterization.
shift assay, there was no detectable AP-1 binding activity
in either normal intestinal mucosa from control animals
or hyperproliferative mucosa from DMH-treated animals
(Figure 2). However, equal amounts of protein extracts
from adenomas and carcinomas showed AP-1 binding (Fig-
ure 2). Supershift experiments using antibodies against
AP-1 proteins confirm that c-Jun, c-Fos, and JunB are
components of this AP-1 complex (data not shown).
ERK and JNK Activity Is Induced in
Intestinal Tumors
Both ERK and JNK pathways can regulate AP-
1 expression and activation.11 ERK phosphorylates and
Figure 2. DMH-induced tumors show increased AP-1 binding activity.
Whole cell extracts derived from transverse colonic mucosa in control
(Con), DMH-treated (DMH), or intestinal tumors samples (DMH-Tumor)
were analyzed for AP-1 binding activity using the DNA mobility shift
assay. Binding reactions were performed by incubating 5 mg of whole
cell extract with a radiolabeled consensus AP-1 probe as described
in Materials and Methods. DNA protein complexes were electropho-
resed on a 5% nondenaturing polyacrylamide gel, followed by autora-
diography. Some reactions contained a 500-fold excess of unlabeled
AP-1 probe as a competitor (/) to demonstrate specificity Additional
competition reactions were performed with a similarly sized probe
representing the consensus binding site of the Sp1 transcription fac-Figure 1. Intestinal mucosa from DMH-treated rats is hyperprolifera-
tor (data not shown). Whole cell extracts from the serum-inducedtive compared with mucosa from control animals. Whole crypt mitotic
murine fibroblas NIH 3T3 cell line (3T3) and the rat intestinal mucosalcount analysis was performed on at least 20 dissected crypts per
cell line IEC-6 (I) were used as positive controls. The last lane containssample from the jejunum and transverse colon of DMH-treated (j)
and control (h) animals, as described in Materials and Methods. only radiolabeled AP-1 probe (P).
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transverse colon from DMH-treated animals comparedactivates the Elk-1 transcription factor, which up-regu-
with levels of JNK activity in transverse colon fromlates expression of the c-fos gene by binding to a serum
controls. JNK activity was measured in intestinal mucosaresponse element site in the c-fos promoter. JNK activates
from the jejunum of control and DMH-treated rats. Al-AP-1 by several mechanisms. First, JNK phosphorylates
though increased JNK activity in hyperproliferative mu-and activates the c-Jun protein directly, increasing AP-
cosa from treated animals was observed, the difference1 activity. Second, because the c-jun gene contains an
between control and DMH-treated animals did not reachAP-1 site in its own promoter, activating c-Jun results
significance. There were no significant regional differ-in up-regulation of the expression of the c-jun gene. In
ences in either JNK or ERK activity for intestinal mucosaaddition, JNK can also phosphorylate the activation
or tumors.domain of Elk-1 and consequently upregulate c-fos ex-
ERK activity was more highly stimulated in intestinalpression.32 To determine which MAPKs are regulating
tumors than JNK activity (Figure 4). Neoplastic tissueAP-1 activation in intestinal neoplasias, ERK and JNK
displayed an approximate 29-fold increase of ERK activ-activities were measured using an in vitro kinase assay.
ity compared with normal-appearing mucosa from theAs shown in Figure 3, there was a strong activation
transverse colon of controls (P Å 0.0024) and a 23-of JNK activity in intestinal neoplasias compared with
fold increase over normal-appearing mucosa from DMH-intestinal mucosa from the transverse colon of control
treated animals (P Å 0.0078). There was no significantrats (23-fold average; P Å 0.0024) or compared with the
difference in ERK activity seen between hyperprolifera-hyperproliferative mucosa from the transverse colon of
tive intestinal mucosa from DMH-treated animals andDMH-treated animals (8.4-fold average; P Å 0.0078).
normal mucosa from control rats in either the transverseThere was a small but significant increase (2.7-fold aver-
colon or jejunum.age; P Å 0.0057) in JNK activity in hyperproliferative
Figure 4. ERK activity is highly stimulated in DMH-induced tumors.
(A ) ERK-1 and ERK-2 proteins were immunoprecipitated from 50 mgFigure 3. JNK activity is greatly increased in DMH-induced tumors.
(A ) Recombinant guanosine triphosphate–c-Jun protein was incubated of whole cell extract from the transverse colon of control rats (control,
1–6), DMH-treated rats (DMH, 7–17), or DMH-induced tumors (DMH-with 50 mg of whole cell extract from the transverse colon of control
rats (Control, 1–6), DMH-treated rats (DMH, 7–17), or DMH-induced Tumor) using a cross-reactive anti–ERK-2 polyclonal antibody. In vitro
kinase reactions were performed on the immune complexes usingtumors (DMH-Tumor). Phosphorylation of guanosine triphosphate–c-
Jun by extract-derived JNK was measured by incorporation of [g- recombinant guanosine triphosphate–Elk protein as a substrate and
[g-32P]ATP as a phosphodonor. Reactions were subjected to SDS-PAGE32P]ATP as determined by SDS-PAGE and PhosphorImager analysis.
Extracts from H-ras–activated and normal 3T3 cells were used as and PhosphorImager analysis. Extracts from 3T3 cells were used as
a positive control when incubated with guanosine triphosphate –Elkpositive controls (/). Extract from normal 3T3 cells, which was incu-
bated with GST alone, was used as a negative control (0). (B ) Quanti- (/) and as a negative control when incubated with GST alone (0).
(B ) Quantitation of activity shown in A from control (h), DMH-treatedtation of activity shown in A from control (h), DMH-treated (j), or
tumor (
 
 ) samples. Inset box shows group averages. (j), or tumor (
 
 ) samples. Inset box shows group averages.
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tumor DNA represents a mixed population of cells, the
following strategy was used to increase the sensitivity of
detecting such mutations. Amplified K-ras products were
subcloned and 30–50 subclones derived from each tumor
were screened by DNA hybridization to wild-type and
mutant K-ras oligonucleotides. A total of 9 of 16 tumors
(56%) were found to have mutations at the second nucle-
otide of either codon 12 or 13 in the K-ras gene (Table
1). Most of these were G r A transitions, as has been
previously reported. However, one tumor contained a G
r C transversion in codon 13, a mutation that has been
observed in human colon cancers. All mutations were
confirmed by DNA sequencing (data not shown). When
the K-ras genotype was compared with JNK and ERK
activity, the presence of a K-ras mutation did not corre-
late with the kinase activity of either JNK or ERK.
Intestinal ERK and JNK Are not Induced
During the Hyperproliferative Response to
Refeeding
Figure 5. MAPK protein levels remain stable in DMH-induced tumors.
The above data suggest that the hyperproliferativeWhole cell extract (50 mg) from the transverse colon of control rats
(Control), DMH-treated rats (DMH), or intestinal tumors (DMH-Tumor) state alone did not activate the ERK and JNK MAPKs.
was separated on 10% SDS-polyacrylamide gels and then transferred To separate the effects of intestinal hyperproliferation
to immobilon-P membranes for Western blot analysis. Immunoblots
from those of tumorigenesis, we used a fasting/refeedingwere probed with (A ) a monoclonal anti-JNK-1 antibody, (B ) a poly-
model to generate hyperproliferative intestinal mucosaclonal anti-ERK2 antibody, or (C ) a polyclonal anti-active ERK antibody
and detected using chemiluminescence. Extract from 3T3 cells con- within the context of normal intestinal growth and devel-
taining an oncogenic H-ras gene (3T3-H61L) was used as a positive opment. Male Sprague–Dawley rats were fasted for 48(/) control.
hours and then refed for 1, 4, or 18 hours before they
were killed. Control animals who were fed ad libitum
were killed at the 18-hour time point. Samples of intesti-To investigate whether any increased JNK and ERK
nal mucosa were then taken from the jejunum and trans-kinase activity observed in DMH-induced neoplasia
verse colon for analysis. Hyperproliferation in the refedcould be attributed to an increase in JNK or ERK protein
intestinal mucosa was shown by measuring ornithine de-levels, Western analysis was performed. No difference in
carboxylase activity, whole crypt mitotic count, and 3H-JNK or ERK protein expression in DMH-induced tu-
thymidine incorporation assays (data not shown).mors compared with mucosa in control animals or hyper-
We examined intestinal mucosa in fasted and refedproliferative mucosa from DMH-treated animals was ob-
rats for JNK and ERK activity. There was no significantserved (Figure 5A and B ). This suggests that the increase
difference in the activity of these MAPKs, for eitherin JNK and ERK kinase activity observed is due to
hypoproliferative or hyperproliferative tissue comparedactivation of these kinases by phosphorylation of their
with tissue derived from ad libitum–fed control. Thisactivating residues by upstream signaling kinases. We
was true for mucosa from both the jejunum and thedirectly assessed this by reprobing the same Western
transverse colon (Figure 6A–D ). Furthermore, there wasblots with antisera specific for the phosphorylated form
no difference in the AP-1 binding activity of these sam-of the activation domain of ERK1/2. Figure 5C shows
ples using the mobility shift assay (data not shown).an increased level of phosphorylated ERK in tumors com-
Western blot analysis shows similar amounts of JNKpared with normal or DMH-treated mucosa.
and ERK proteins in control, hypoproliferative, and hy-
K-ras Mutations in Intestinal Tumors perproliferative intestinal mucosa (Figure 6E–H ). These
observations suggest that hyperproliferation, whether in-Because activating mutations in K-ras occur in
about 50% of colon cancers and Ras can activate both duced by a carcinogen or fasting/refeeding, is not suffi-
cient to activate the JNK and ERK MAPKs in intestinalJNK and ERK, we examined the intestinal tumors in-
duced by DMH treatment for K-ras mutations. Because mucosa in vivo.
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Figure 6. MAPK activity and protein levels do not change during fasting and refeeding treatment. (A–D) Intestinal mucosa derived from the
(A ) transverse colon or (B ) jejunum of fasted and refed rats was analyzed for JNK activity as described above. Extracts were from rats that
were fasted for 48 hours and not refed (0 hr), refed for 1 hour (1 hr), 4 hours (4 hr), 18 hours (18 hr), or fed ad libitum throughout the
experiment (ad lib). Similarly, ERK activity was assessed in extracts from the (C ) transverse colon or (D) jejunum using the methods described.
Positive controls (/) included extracts from the serum-induced 3T3 cell line and two separate extract preparations from 3T3 cells expressing
an activated H-ras gene, respectively. (E–H) Western blot analysis was performed as described above using 50 mg of whole cell mucosal
extracts from the (E and G) transverse colon or (F and H) jejunum. Immunoblots were probed for (E and F ) JNK-1 protein or (G and H) ERK
proteins. Extracts from 3T3 cells were used as positive (/) and negative (0) controls; the (0) control lane was incubated with secondary
antibody only.
activity between humans and rats or may result fromDiscussion
variation in the technical approaches. Increased levels of
The early events leading to colorectal carcinogene-
activated ERK protein in tumors was demonstrated in
sis are largely unknown. Although it has been observed Western blots using antisera specific for the phosphory-
that intestinal hyperproliferation precedes the formation lated form of the ERK activation domain. However,
of intestinal tumors, the relationship between hyperpro- Western blot analysis using antisera against total ERK
liferation and the subsequent accumulation of mutations protein showed similar amounts of ERK with no change
that mediate tumorigenesis is not clear. Because MAPK in the apparent molecular weight between tumors and
signaling plays a key role in proliferation, we have inves- normal mucosa. This was a surprising result because pre-
tigated the role of these pathways in colonic proliferation vious studies in cultured cells showed a shift in the appar-
and tumorigenesis in vivo. This study demonstrates ent molecular weight due to the phosphorylation of the
strong activation of both the JNK and ERK signal trans- ERK activation domain. However, this study and a recent
duction pathways in intestinal adenomas and carcinomas, study of primary gastric cells34 show this indirect assay
but not during intestinal hyperproliferation. Activation for ERK activation is not valid in certain tissues. The
of JNK in adenomas and carcinomas was 23-fold on absence of a shift in the apparent molecular weight may
average over that of control mucosa; ERK was activated represent the net effect of multiple phosphorylation sites
on average 29-fold over control levels. In addition, AP- on ERK proteins.
1 binding activity was strongly induced in intestinal Based on the different sizes, location, and histology
tumors. While both JNK and ERK regulate AP-1 activ- of the adenomas/carcinomas induced by DMH treat-
ity, they do so via separate pathways and activation of ment, different potential for growth and invasiveness
different targets.11 would be expected between samples. Therefore, it is
These results contradict a previous study reporting a not surprising that the level of activation observed in
twofold decrease in activity of the ERK MAPKs in hu- JNK and ERK activity varied widely between tumors.
It is interesting to note that the histological grade ofman colon tumors.33 This may reflect differences in ERK
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adenoma/carcinoma did not predict the fold activation whereas all the adenomas and carcinomas examined in
seen in the kinase activity, although we did observe a our study displayed elevated JNK and ERK activity,
trend of increasing invasiveness with higher JNK or only 56% contained a mutation in K-ras. Thus, although
ERK kinase activity. activated Ras probably contributes to JNK and ERK
We did not observe activation of these kinases in hy- activation in K-ras mutated tumors, it is unlikely that
perproliferative intestinal epithelium using two indepen- Ras pathways are the only mechanism responsible for the
dent models, DMH treatment and fasting/refeeding. A changes in activity of these MAPKs in colonic adenomas
hyperproliferative epithelium is thought to be the first and carcinomas. Although in vitro studies using homolo-
histological change in the adenoma-carcinoma sequence gous recombination to knock-out K-ras demonstrate a
of colonic carcinogenesis.1 However, the correlation be- critical role for Ras in the growth characteristics of colon
tween increases in proliferation and the risk of tumor carcinoma cells,19,20 our data suggest that Ras effector
development is controversial. Although a large body of pathways other than those leading to JNK and ERK
data supports the idea that proliferative changes precede activation may be most important.
tumor formation,2,4,5,35,36 some studies fail to show a cor- Several known pathways may be responsible for the
relation between measurements of cellular proliferation activation of JNK and ERK during colonic carcinogene-
and the risk of developing adenomas and carcinomas,37,38 sis. JNK can be activated by a TNF-a–mediated Ras-
calling into question the usefulness of proliferation mea- independent pathway, whereas protein kinase C can
sures as intermediate biomarkers. Our data show that activate the ERK pathway through direct activation of
activation of JNK and ERK, and consequent AP-1 acti- Raf-1,42–44 bypassing Ras. Furthermore, the elevated lev-
vation, occurs at a stage after the proliferative changes els and activity of c-Src found during the progression of
seen in the intestinal mucosa during tumorigenesis. The colonic carcinogenesis45–47 may contribute to the activa-
fact that AP-1 activation correlates only with a change to tion of JNK and ERK because v-Src has been shown to
frank neoplasia, and not with an increase in proliferation, directly activate c-Raf, as well as cooperate with Ras48
suggests that AP-1 may play an important role in later and activate JNK.49
neoplastic growth. This study suggests that AP-1 activation may be im-
Both JNK and ERK pathways that regulate AP-1 can portant in colorectal cancers induced by the carcinogen
be activated by Ras.11 Mutations in K-ras occur in 40%– DMH. This activation occurs by a complex mechanism,
50% of human colorectal carcinomas.39 Previous studies using at least two separate signal transduction pathways.
have shown that one third to two thirds of DMH-induced It remains to be investigated whether similar results will
tumors have K-ras mutations in the second position of be found in other genetic models, such as min mice, or
codon 12 or 13. Unlike K-ras mutations found in spo- naturally occurring colon cancers. A logical extension of
radic human colonic tumors, these mutations are almost this study is to determine if activation of AP-1 is neces-
exclusively G r A transitions.18 This is most likely due sary for colonic tumorigenesis. The DMH-induced colon
to the action of DMH, which induces O6-methylguanine carcinoma model can be used to address this question in
adduct formation, thereby leading to G r A transitions vivo. The well-characterized nature of these signaling
as a result of mispairing.40,41 We show in the present pathways will allow for individual components of these
study that 8 of 16 DMH-induced tumors have one of cascades to be manipulated and permit one pathway or
these K-ras mutations, while 1 additional tumor contains the other to be selectively blocked. If blocking AP-1
a G r C transversion. Although we cannot rule out activation prevents transformation, it may be possible to
use inhibitors of this activation as therapeutic tools inother K-ras mutations undetectable with our probes, for
human colorectal cancer. Finally, determining which AP-example in codon 59, these are unlikely given previous
1 responsive genes are important in tumorigenesis wouldstudies in the DMH model.18
allow for the identification of proteins that might beBecause K-ras mutations have been detected in both
targeted to develop cancer therapies.adenomas and normal mucosa adjacent to neoplasia, our
results suggest that elevation of JNK and ERK activities
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